Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;20(12):1433-8.
doi: 10.1016/j.drudis.2015.05.013. Epub 2015 Jul 3.

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform

Amber Johnson  1 , Jia Zeng  1 , Ann M Bailey  1 , Vijaykumar Holla  1 , Beate Litzenburger  1 , Humberto Lara-Guerra  1 , Gordon B Mills  2 , John Mendelsohn  3 , Kenna R Shaw  1 , Funda Meric-Bernstam  4
Affiliations

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform

Amber Johnson et al. Drug Discov Today. 2015 Dec.

Abstract

The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart for deciphering whether the genetic variant is actionable. This flowchart represents the questions asked (diamonds) and possible information determined (parallelograms) to reach an answer (circles) regarding whether a genetic alteration or variant is actionable.
See this image and copyright information in PMC

References

    1. Le Tourneau C, et al. Randomised proof-of-concept Phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer. 2014;111:17–24. - PMC - PubMed
    1. Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:997–4013. - PubMed
    1. Smith I, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36. - PubMed
    1. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. - PubMed
    1. Welch BM, Kawamoto K. The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information. J Pers Med. 2013;3:306–325. - PMC - PubMed

Substances

LinkOut - more resources